ReP USP - Resultado da busca

Artigo de periodico
Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer (2023)
Gardani, Carla Fernanda Furtado; Pedrazza, Eduardo Luiz; Paz, Victória Santos; Zanirati, Gabriele Goulart; Costa, Jaderson Costa da; Andrejew, Roberta ; Ulrich, Henning ; Scholl, Juliete Nathali ; Figueiró, Fabrício ; Rockenbach, Liliana ; Morrone, Fernanda Bueno
Fonte: Pharmaceuticals. Unidade: IQ
Assuntos: NEOPLASIAS PROSTÁTICAS, CITOMETRIA DE FLUXO, HIDRÓLISE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARDANI, Carla Fernanda Furtado et al. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, v. 16, p. 1-17 art. 1619, 2023Tradução . . Disponível em: https://dx.doi.org/10.3390/ph16111619. Acesso em: 26 ago. 2024.
APA
Gardani, C. F. F., Pedrazza, E. L., Paz, V. S., Zanirati, G. G., Costa, J. C. da, Andrejew, R., et al. (2023). Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, 16, 1-17 art. 1619. doi:10.3390/ph16111619
NLM
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 ago. 26 ] Available from: https://dx.doi.org/10.3390/ph16111619
Vancouver
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 ago. 26 ] Available from: https://dx.doi.org/10.3390/ph16111619
Artigo de periodico
Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients (2022)
Pietrobon, Anna Julia ; Andrejew, Roberta ; Custodio, Ricardo Wesley Alberca ; Oliveira, Luana de Mendonça ; Scholl, Juliete Nathali ; Teixeira, Franciane Mouradian Emidio ; Brito, Cyro Alves de ; Glaser, Talita ; Kazmierski, Julia ; Goffinet, Christine ; Turdo, Anna Claudia; Yendo, Tatiana Mina ; Aoki, Valeria; Figueiró, Fabrício; Battastini, Ana Maria ; Ulrich, Henning ; Benard, Gil ; Duarte, Alberto José da Silva; Sato, Maria Notomi
Fonte: Frontiers in Immunology. Unidades: FM, IQ, ICB
Assuntos: COVID-19, PURINAS, ADENOSINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIETROBON, Anna Julia et al. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Frontiers in Immunology, v. 13, p. 1-12 art. 1012027, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.1012027. Acesso em: 26 ago. 2024.
APA
Pietrobon, A. J., Andrejew, R., Custodio, R. W. A., Oliveira, L. de M., Scholl, J. N., Teixeira, F. M. E., et al. (2022). Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Frontiers in Immunology, 13, 1-12 art. 1012027. doi:10.3389/fimmu.2022.1012027
NLM
Pietrobon AJ, Andrejew R, Custodio RWA, Oliveira L de M, Scholl JN, Teixeira FME, Brito CA de, Glaser T, Kazmierski J, Goffinet C, Turdo AC, Yendo TM, Aoki V, Figueiró F, Battastini AM, Ulrich H, Benard G, Duarte AJ da S, Sato MN. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients [Internet]. Frontiers in Immunology. 2022 ; 13 1-12 art. 1012027.[citado 2024 ago. 26 ] Available from: https://doi.org/10.3389/fimmu.2022.1012027
Vancouver
Pietrobon AJ, Andrejew R, Custodio RWA, Oliveira L de M, Scholl JN, Teixeira FME, Brito CA de, Glaser T, Kazmierski J, Goffinet C, Turdo AC, Yendo TM, Aoki V, Figueiró F, Battastini AM, Ulrich H, Benard G, Duarte AJ da S, Sato MN. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients [Internet]. Frontiers in Immunology. 2022 ; 13 1-12 art. 1012027.[citado 2024 ago. 26 ] Available from: https://doi.org/10.3389/fimmu.2022.1012027
Artigo de periodico
Interference of ursolic acid treatment with glioma growth: an in vitro and in vivo study (2017)
Bergamin, Letícia Scussel; Figueiró, Fabrício; Dietrich, Fabrícia; Manica, Fabiana de Mattos; Chiela, Eduardo C. Filippi; Mendes, Franciane Brackman; Jandrey, Elisa Helena Farias; Lopes, Daniela Vasconcelos; Oliveira, Francine H; Nascimento, Isis C; Ulrich, Henning ; Battastini, Ana Maria Oliveira
Fonte: European Journal of Pharmacology. Unidade: IQ
Assunto: GLIOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERGAMIN, Letícia Scussel et al. Interference of ursolic acid treatment with glioma growth: an in vitro and in vivo study. European Journal of Pharmacology, v. 811, p. 268-275, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2017.06.030. Acesso em: 26 ago. 2024.
APA
Bergamin, L. S., Figueiró, F., Dietrich, F., Manica, F. de M., Chiela, E. C. F., Mendes, F. B., et al. (2017). Interference of ursolic acid treatment with glioma growth: an in vitro and in vivo study. European Journal of Pharmacology, 811, 268-275. doi:10.1016/j.ejphar.2017.06.030
NLM
Bergamin LS, Figueiró F, Dietrich F, Manica F de M, Chiela ECF, Mendes FB, Jandrey EHF, Lopes DV, Oliveira FH, Nascimento IC, Ulrich H, Battastini AMO. Interference of ursolic acid treatment with glioma growth: an in vitro and in vivo study [Internet]. European Journal of Pharmacology. 2017 ; 811 268-275.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1016/j.ejphar.2017.06.030
Vancouver
Bergamin LS, Figueiró F, Dietrich F, Manica F de M, Chiela ECF, Mendes FB, Jandrey EHF, Lopes DV, Oliveira FH, Nascimento IC, Ulrich H, Battastini AMO. Interference of ursolic acid treatment with glioma growth: an in vitro and in vivo study [Internet]. European Journal of Pharmacology. 2017 ; 811 268-275.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1016/j.ejphar.2017.06.030
Artigo de periodico
Ecto-5’-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model (2015)
Cappellari, Angélica Regina; Pillat, Micheli Mainardi; Souza, Hellio Danny Nobrega de; Dietrich, Fabrícia; Oliveira, Francine H; Figueiró, Fabrício; Abujamra, Ana L; Roesler, Rafael; Lecka, Joanna; Sévigny, Jean; Battastini, Ana Maria Oliveira; Ulrich, Henning
Fonte: PLOS ONE. Unidade: IQ
Assuntos: MEDULOBLASTOMA, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAPPELLARI, Angélica Regina et al. Ecto-5’-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model. PLOS ONE, v. 10, n. 10, p. 1-18 art. e0140996, 2015Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0140996. Acesso em: 26 ago. 2024.
APA
Cappellari, A. R., Pillat, M. M., Souza, H. D. N. de, Dietrich, F., Oliveira, F. H., Figueiró, F., et al. (2015). Ecto-5’-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model. PLOS ONE, 10( 10), 1-18 art. e0140996. doi:10.1371/journal.pone.0140996
NLM
Cappellari AR, Pillat MM, Souza HDN de, Dietrich F, Oliveira FH, Figueiró F, Abujamra AL, Roesler R, Lecka J, Sévigny J, Battastini AMO, Ulrich H. Ecto-5’-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model [Internet]. PLOS ONE. 2015 ; 10( 10): 1-18 art. e0140996.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1371/journal.pone.0140996
Vancouver
Cappellari AR, Pillat MM, Souza HDN de, Dietrich F, Oliveira FH, Figueiró F, Abujamra AL, Roesler R, Lecka J, Sévigny J, Battastini AMO, Ulrich H. Ecto-5’-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model [Internet]. PLOS ONE. 2015 ; 10( 10): 1-18 art. e0140996.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1371/journal.pone.0140996

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento

Afiliação dos autores externos não normalizada